Histological subtypes of periocular basal cell carcinoma

Wu, Albert Y.; Sun, Michelle T.; Huilgol, Shyamala C.; Madge, Simon N.; Selva, Dinesh

doi:10.1111/ceo.12298

Cited by 29 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In comparison, the percentage of aggressive histological types (infiltrative, metatypical, micronodular and desmoplastic) in our group was 49·0%, with the most common aggressive type being micronodular. The distribution of types of BCC in this study was similar, with the exception of a larger proportion of aggressive BCCs, to a large study from South Australia …”

Section: Discussionsupporting

confidence: 83%

Growth of periocular basal cell carcinomas

Tan¹,

Lin

Sheck

et al. 2015

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 83%

Growth of periocular basal cell carcinomas

Tan¹,

Lin

Sheck

et al. 2015

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…6,8 This statement can be affirmed in accordance with a retrospective study carried out in Australia for a period of seven years (2006 to 2012) which have discovered BCC occurring more frequently on the lower lid. 6 An early study in central India also demonstrated similar finding.…”

Section: Discussionsupporting

confidence: 53%

“…This finding is particularly constant with previous study in Oradea while interestingly, most other studies describing nodular BCC as the most common histological type. 2,6,9,11 There are limitations in this study where this study may not represent the entire Bandung population. Nonetheless, this study provides a compelling overview of BCC as a basis of upcoming research and essential information for physicians and the community.…”

Section: Discussionmentioning

confidence: 99%

“…6,9 This phenomenon may be explained by the vehicle composition in Indonesian cities with a threefold proportion of motorcycles than cars. 10 Histologically, the most common subtype is represented by solid growth pattern.…”

Section: Discussionmentioning

confidence: 99%

“…Many studies overseas have shown that basal cell carcinoma (BCC) represents the most common malignant eyelid tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma and/or malignant melanoma. [2][3][4][5][6][7] Basal cell carcinoma is the most common invasive cancer in humans. It is a slowly enlarging, locally invasive neoplasm arising from epidermal basal cells and is capable of extensive tissue destruction.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Characteristics of Malignant Eyelid Basal Cell Carcinoma in Cicendo Eye Hospital Bandung from 2013 to 2015

Hui¹,

Kartiwa²,

Dwiwina³

2017

amj

View full text Add to dashboard Cite

Background: Basal cell carcinoma (BCC) has been proved to have the highest incidence among eyelid malignancies. Basal cell carcinoma is the most common invasive cancer in humans. It is capable of causing extensive tissue destruction. The aim of the study was to identify the characteristics of adult patients with malignant eyelid BCC in Cicendo Eye Hospital Bandung. Methods: A descriptive retrospective study was conducted to determine the characteristics of adult patients with malignant eyelid BCC in Cicendo Eye Hospital Bandung from March 2013 to October 2015. Age and sex distribution of the lesions, location and histopathological results of the tumors were stratified as variables. The inclusion criteria were patients over age of 20, histopathologically diagnosed with periocular BCC. Results: A total of 37 cases histopathologically diagnosed with periocular BCC were evaluated. Females had a slight predominance. The mean age was 61.7 years. The most common site was on the lower lid. The tumors occurred more on the left side. The most common histological subtype was represented by solid growth pattern.

show abstract

Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial

et al. 2020

View full text Add to dashboard Cite

IMPORTANCEThe outcomes of vismodegib treatment in a relatively large cohort of study participants with periocular locally advanced basal cell carcinoma (POLA-BCC) may guide physicians when considering this treatment.OBJECTIVE To report the outcomes of vismodegib treatment in patients with POLA-BCC in the Safety Events in Vismodegib (STEVIE) study. DESIGN, SETTING, AND PARTICIPANTSThis post hoc subgroup analysis from the STEVIE single-arm, multicenter, open-label cohort study screened all 1215 participants for ocular or periocular involvement and identified 244 participants with POLA-BCC or metastatic BCC. Data for the first STEVIE trial were collected from 167 treatment locations in 36 countries from June 30, 2011, to June 14, 2017. This post hoc analysis was performed from April 1 to August 31, 2019. MAIN OUTCOMES AND MEASURESResponse to treatment and adverse events. RESULTS Ocular or periocular involvement was found in 244 of 1215 STEVIE participants (20.1%), who constituted the analytic sample. The median age of the study participants was 72.0 (interquartile range [IQR], 60.0-82.0]) years, and they included 143 men (58.6%). Locally advanced BCC was diagnosed in 238 of the 244 participants (97.5%) and metastatic BCC, in 6 (2.5%). The median duration of exposure to vismodegib was 40.0 (IQR, 20.0-78.0) weeks, specifically 39.7 (IQR, 19.9-76.0) weeks for POLA-BCC and 92.4 (IQR, 53.2-163.0) weeks for metastatic BCC. Sixty-nine participants (28.3%) sustained serious adverse events (alopecia, muscle spasms, dysgeusia, weight loss, decreased appetite, asthenia, ageusia, nausea, fatigue, and diarrhea). Two hundred thirty-two study participants (95.1%) sustained more than 1 adverse effect. The overall mean (SD) number of drug-related adverse effects per study participant by first adverse event, regardless of the severity, was 5.48 (3.84). Discontinuation of vismodegib treatment owing to an adverse event was recorded in 58 participants (23.8%). During the study, 22 participants (9.0%) died, 70 (28.7%) achieved complete response, and 94 (38.5%) achieved partial response. CONCLUSIONS AND RELEVANCEVismodegib was well tolerated by the study participants with POLA-BCC. The safety of vismodegib treatment according to the STEVIE trial findings is consistent with that reported in previous studies. These data may be helpful when considering vismodegib for patients with POLA-BCC.

show abstract

Histological subtypes of periocular basal cell carcinoma

Abstract: Background: To determine the proportion of different subtypes of periocular BCC in South Australia.

Cited by 29 publications

References 27 publications

Growth of periocular basal cell carcinomas

Growth of periocular basal cell carcinomas

Characteristics of Malignant Eyelid Basal Cell Carcinoma in Cicendo Eye Hospital Bandung from 2013 to 2015

Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial

Contact Info

Product

Resources

About